JP2020517259A - 操作された抗原受容体を発現する免疫細胞 - Google Patents

操作された抗原受容体を発現する免疫細胞 Download PDF

Info

Publication number
JP2020517259A
JP2020517259A JP2019556918A JP2019556918A JP2020517259A JP 2020517259 A JP2020517259 A JP 2020517259A JP 2019556918 A JP2019556918 A JP 2019556918A JP 2019556918 A JP2019556918 A JP 2019556918A JP 2020517259 A JP2020517259 A JP 2020517259A
Authority
JP
Japan
Prior art keywords
cells
antigen
cell
immune
immune cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019556918A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020517259A5 (enExample
Inventor
ケイティ レズバニ
ケイティ レズバニ
エリザベス ジェイ． シュパル
エリザベス ジェイ． シュパル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The University of Texas System
Original Assignee
The University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University of Texas System filed Critical The University of Texas System
Publication of JP2020517259A publication Critical patent/JP2020517259A/ja
Publication of JP2020517259A5 publication Critical patent/JP2020517259A5/ja
Priority to JP2023083056A priority Critical patent/JP2023109901A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22062—Caspase-9 (3.4.22.62)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
JP2019556918A 2017-04-19 2018-04-19 操作された抗原受容体を発現する免疫細胞 Pending JP2020517259A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023083056A JP2023109901A (ja) 2017-04-19 2023-05-19 操作された抗原受容体を発現する免疫細胞

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762487248P 2017-04-19 2017-04-19
US62/487,248 2017-04-19
PCT/US2018/028418 WO2018195339A1 (en) 2017-04-19 2018-04-19 Immune cells expressing engineered antigen receptors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023083056A Division JP2023109901A (ja) 2017-04-19 2023-05-19 操作された抗原受容体を発現する免疫細胞

Publications (2)

Publication Number Publication Date
JP2020517259A true JP2020517259A (ja) 2020-06-18
JP2020517259A5 JP2020517259A5 (enExample) 2021-05-20

Family

ID=63856923

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019556918A Pending JP2020517259A (ja) 2017-04-19 2018-04-19 操作された抗原受容体を発現する免疫細胞
JP2023083056A Ceased JP2023109901A (ja) 2017-04-19 2023-05-19 操作された抗原受容体を発現する免疫細胞

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023083056A Ceased JP2023109901A (ja) 2017-04-19 2023-05-19 操作された抗原受容体を発現する免疫細胞

Country Status (8)

Country Link
US (3) US11344578B2 (enExample)
EP (2) EP3612210A4 (enExample)
JP (2) JP2020517259A (enExample)
KR (2) KR20240059648A (enExample)
CN (1) CN110753555A (enExample)
AU (1) AU2018256436B2 (enExample)
CA (1) CA3060443A1 (enExample)
WO (1) WO2018195339A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023504782A (ja) * 2019-11-27 2023-02-07 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｂ細胞のｃａｒ形質導入とｃｒｉｓｐｒ遺伝子編集との大規模での組み合わせ
JP2023540022A (ja) * 2020-08-24 2023-09-21 シャリテ－ウニベルジテーツメディツィン ベルリン チェックポイント阻害分子及び免疫刺激性サイトカインをコードするキメラ抗原受容体構築物、並びにＣＤ４４ｖ６を認識するＣＡＲ発現細胞
JP2024532876A (ja) * 2021-08-24 2024-09-10 アストラゼネカ・アクチエボラーグ プライマリー免疫細胞を作製するための方法

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12350349B2 (en) 2016-08-03 2025-07-08 Washington University Gene editing of CAR-T cells for the treatment of T cell malignancies with chimeric antigen receptors
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
WO2019165121A1 (en) 2018-02-21 2019-08-29 Board Of Regents, The University Of Texas System Methods for activation and expansion of natural killer cells and uses therof
WO2019210293A1 (en) * 2018-04-27 2019-10-31 Baylor College Of Medicine Car t cells with one or more interleukins
SG11202010763VA (en) * 2018-05-03 2020-11-27 Univ Texas Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blockade
US20200040056A1 (en) * 2018-05-31 2020-02-06 Washington University Genome-edited invariant natural killer t (inkt) cells for the treatment of hematologic malignancies
KR102907902B1 (ko) * 2018-08-01 2026-01-02 난트퀘스트, 인크. 면역 요법의 안정한 유전적 변형을 위한 귀소 수용체 또는 사이토카인, 및 키메라 항원 수용체를 포함하는 4 시스트론 시스템
US12624086B2 (en) 2018-10-31 2026-05-12 Mayo Foundation For Medical Education And Research Materials and methods for treating cancer
US12257286B2 (en) 2018-10-31 2025-03-25 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
US12264189B2 (en) 2018-10-31 2025-04-01 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
AU2019386140B2 (en) * 2018-11-28 2026-05-28 Board Of Regents, The University Of Texas System Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
BR112021016046A2 (pt) * 2019-02-15 2021-11-09 Editas Medicine Inc Células assassinas naturais modificadas (nk) para imunoterapia
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
EP3947647A4 (en) * 2019-03-29 2023-01-04 Board of Regents, The University of Texas System METHODS OF MANUFACTURE OF CAR NK CELLS AND USE THEREOF
JP7711945B2 (ja) 2019-04-30 2025-07-23 センティ バイオサイエンシズ インコーポレイテッド キメラ受容体及びその使用方法
CN114174325A (zh) * 2019-06-04 2022-03-11 恩卡尔塔公司 用于免疫疗法的工程化自然杀伤细胞和工程化t细胞的组合
CA3145223A1 (en) * 2019-07-23 2021-01-28 Wen Yang Composition and method for adoptive immunotherapy
WO2021035078A1 (en) * 2019-08-21 2021-02-25 Akeso Therapeutics, Inc. Type iii nkt cells and related compositions and methods
CN114651003A (zh) 2019-09-10 2022-06-21 黑曜石疗法公司 用于可调调节的ca2-il15融合蛋白
JP2022548902A (ja) * 2019-09-18 2022-11-22 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｂｃｍａ陽性腫瘍を標的とするためのナチュラルキラー細胞の操作方法
US20210106619A1 (en) * 2019-10-10 2021-04-15 Nantkwest, Inc. NK-92 Bone and Brain targeting
CN115297873A (zh) * 2019-11-08 2022-11-04 梅约医学教育与研究基金会 利用工程化改造的间充质干细胞治疗炎症和退行性疾病的方法和物质
CN114929853A (zh) * 2019-11-27 2022-08-19 得克萨斯大学体系董事会 用于治疗胶质母细胞瘤和其他癌症的天然杀伤细胞免疫疗法
EP4065696A4 (en) * 2019-11-27 2024-02-07 Board of Regents, The University of Texas System Large-scale combined car transduction and crispr gene editing of t cells
CA3163258A1 (en) * 2019-11-27 2021-06-03 Board Of Regents, The University Of Texas System Large-scale combined car transduction and crispr gene editing of nk cells
EP4065138A4 (en) * 2019-11-27 2024-02-28 Board of Regents, The University of Texas System LARGE-SCALE COMBINED CAR TRANSDUCTION AND CRISPR GENE EDITING OF MSC CELLS
CN114929250A (zh) * 2019-12-18 2022-08-19 爱迪塔斯医药公司 用于疗法的经工程化的细胞
BR112022013445A2 (pt) * 2020-01-08 2022-09-13 Univ Texas Método de modificação de células exterminadoras naturais para direcionar tumores cd70-positivos
US11230699B2 (en) 2020-01-28 2022-01-25 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
CN111269326A (zh) * 2020-02-28 2020-06-12 南京北恒生物科技有限公司 新型嵌合抗原受体及其用途
JP7773789B2 (ja) 2020-03-28 2025-11-20 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 癌の治療のための細胞免疫療法
CN113913458A (zh) * 2020-07-09 2022-01-11 杭州优凯瑞医药科技有限公司 非病毒方法制备稳定高表达嵌合受体的nk细胞
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
EP4255453A4 (en) * 2020-12-03 2025-03-26 Nkarta, Inc. Methods for manipulating immune cells for increased potency and persistence, as well as uses of engineered cells in immunotherapy
EP4271798A1 (en) 2020-12-30 2023-11-08 CRISPR Therapeutics AG Compositions and methods for differentiating stem cells into nk cells
CA3228692A1 (en) * 2021-08-30 2023-03-09 Edward L. Perkins Tcd34 and other markers for identification and sorting of cells and for use as in vivo tracking assistant
WO2024100604A1 (en) 2022-11-09 2024-05-16 Juno Therapeutics Gmbh Methods for manufacturing engineered immune cells
US20260232729A1 (en) 2023-02-03 2026-08-13 C3S2 Gmbh Methods for non-viral manufacturing of engineered immune cells
AU2023447316A1 (en) * 2023-05-05 2025-11-20 Board Of Regents, The University Of Texas System Multi-receptor natural killer cells
CN116410336B (zh) * 2023-06-02 2023-09-22 云南赛元生物技术有限公司 一种嵌合抗原受体的编码核苷酸、car-nk细胞及其构建方法和应用
EP4574838A1 (en) 2023-12-21 2025-06-25 Vilnius University Chimeric antigen receptor (car) with enhanced recruitment of signaling partners
WO2025158400A1 (en) * 2024-01-24 2025-07-31 Yale University Compositions and methods of natural killer cell hyperboosts for enhancement of nk cell therapy

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007528862A (ja) * 2003-07-16 2007-10-18 アールブイエックス セラピューティクス， インコーポレイテッド ＴＧＦ−βの効果を下方制御するための化合物および方法
JP2010508850A (ja) * 2006-11-13 2010-03-25 サンガモ バイオサイエンシズ インコーポレイテッド ヒトグルココルチコイド受容体遺伝子座の修飾のための方法および組成物
WO2012136231A1 (en) * 2010-09-08 2012-10-11 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Interleukin 15 as selectable marker for gene transfer in lymphocytes
US20140255363A1 (en) * 2011-09-16 2014-09-11 Baylor College Of Medicine Targeting the tumor microenvironment using manipulated nkt cells
WO2017023803A1 (en) * 2015-07-31 2017-02-09 Regents Of The University Of Minnesota Modified cells and methods of therapy

Family Cites Families (314)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59204036A (ja) 1983-05-06 1984-11-19 Dainippon Ink & Chem Inc レジストパタ−ンの形成法
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US4981784A (en) 1987-12-02 1991-01-01 The Salk Institute For Biological Studies Retinoic acid receptor method
US5171671A (en) 1987-12-02 1992-12-15 The Salk Institute For Biological Studies Retinoic acid receptor composition
US4870287A (en) 1988-03-03 1989-09-26 Loma Linda University Medical Center Multi-station proton beam therapy system
US5906936A (en) 1988-05-04 1999-05-25 Yeda Research And Development Co. Ltd. Endowing lymphocytes with antibody specificity
US5602009A (en) 1988-12-23 1997-02-11 The Salk Institute For Biological Studies Dominant negative chimeras of the steroid/thyroid superfamily of receptors
US5164897A (en) 1989-06-21 1992-11-17 Techpower, Inc. Automated method for selecting personnel matched to job criteria
ES2152920T3 (es) 1990-02-09 2001-02-16 Salk Inst For Biological Studi Composiciones receptoras de retinoides y metodos.
JPH06505152A (ja) 1990-12-21 1994-06-16 ザ ロックフェラー ユニヴァーシティ 肝集積性転写因子
US5851828A (en) 1991-03-07 1998-12-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
US5912170A (en) 1991-03-07 1999-06-15 The General Hospital Corporation Redirection of cellular immunity by protein-tyrosine kinase chimeras
US7049136B2 (en) 1991-03-07 2006-05-23 The General Hospital Corporation Redirection of cellular immunity by receptor chimeras
US5843728A (en) 1991-03-07 1998-12-01 The General Hospital Corporation Redirection of cellular immunity by receptor chimeras
US6004811A (en) 1991-03-07 1999-12-21 The Massachussetts General Hospital Redirection of cellular immunity by protein tyrosine kinase chimeras
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
US6090914A (en) 1991-06-27 2000-07-18 Bristol-Myers Squibb Company CTLA4/CD28Ig hybrid fusion proteins and uses thereof
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
DE59208378D1 (de) 1991-09-04 1997-05-28 Ciba Geigy Ag Verfahren zur Herstellung von Glykosiden
ATE215601T1 (de) 1991-09-17 2002-04-15 Salk Inst For Biological Studi Rezeptoren der steroid/thyroid superfamilie von rezeptoren
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US6416998B1 (en) 1992-09-02 2002-07-09 Baylor College Of Medicine Plasmid encoding a modified steroid hormone
US5789187A (en) 1992-08-27 1998-08-04 Worcester Foundation For Experimental Biology Identification of differentiation factor receptors which inhibit the tumorigenicity of neuroblastoma cells in a ligand-independent manner
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5552303A (en) 1993-03-08 1996-09-03 Immunex Corporation DNA encoding epithelium-derived T-cell factor
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
AU695869B2 (en) 1993-04-06 1998-08-27 Fred Hutchinson Cancer Research Center Chimeric cytokine receptors in lymphocytes
JPH08506247A (ja) 1993-07-09 1996-07-09 アムジェン ボールダー インコーポレイテッド 組換えｃｔｌａ４ポリペプチドおよびその製造方法
IL110298A (en) 1993-07-13 1999-04-11 Brann Mark Robert Identification of ligands by selective amplification of cells transfected with receptors
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
AU685693B2 (en) 1994-11-01 1998-01-22 Targeted Genetics Corporation Chimeric receptors for the generation of selectively-activatable TH-independent cytotoxic T cells
US6005086A (en) 1995-01-13 1999-12-21 The Salk Institute For Biological Studies Farnesoid activated receptor polypeptides, and nucleic acid encoding the same
US5935821A (en) 1995-01-17 1999-08-10 Board Of Trustees Of The University Of Kentucky Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
US5712149A (en) 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
US6103521A (en) 1995-02-06 2000-08-15 Cell Genesys, Inc. Multispecific chimeric receptors
WO1996027392A1 (en) 1995-03-08 1996-09-12 The Scripps Research Institute Antigen presenting system and methods for activation of t-cells
US5763270A (en) 1995-06-07 1998-06-09 Genemedicine, Inc. Plasmid for delivery of nucleic acids to cells and methods of use
WO1997005252A2 (en) 1995-07-26 1997-02-13 Nps Pharmaceuticals, Inc. Chimeric receptors and methods for identifying compounds active at metabotropic glutamate receptors and the use of such compounds in the treatment of neurological disorders and diseases
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5750353A (en) 1995-12-11 1998-05-12 New England Medical Center Hospitals, Inc. Assay for non-peptide agonists to peptide hormone receptors
US6084084A (en) 1996-02-21 2000-07-04 Nps Pharmaceuticals, Inc. Human metabotropic glutamate receptor
US6451995B1 (en) 1996-03-20 2002-09-17 Sloan-Kettering Institute For Cancer Research Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods
US5760395A (en) 1996-04-18 1998-06-02 Universities Research Assoc., Inc. Method and apparatus for laser-controlled proton beam radiology
JP2001502521A (ja) 1996-04-26 2001-02-27 ベス イスラエル デアコネス メディカル センター インターロイキン―１５の拮抗剤
US6451308B1 (en) 1996-04-26 2002-09-17 Beth Israel Deaconess Medical Center Antagonists of interleukin-15
IL126843A (en) 1996-05-23 2007-06-17 Scripps Research Inst Mhc class ii antigen-presenting systems and methods for activating cd4+t cells in vitro
US5739169A (en) 1996-05-31 1998-04-14 Procept, Incorporated Aromatic compounds for inhibiting immune response
US5844905A (en) 1996-07-09 1998-12-01 International Business Machines Corporation Extensions to distributed MAC protocols with collision avoidance using RTS/CTS exchange
US7196164B2 (en) 1997-07-08 2007-03-27 Human Genome Sciences, Inc. Secreted protein HHTLF25
EP0970128A1 (en) 1997-03-21 2000-01-12 Brigham And Women's Hospital Immunotherapeutic ctla-4 binding peptides
US6120669A (en) 1997-04-16 2000-09-19 Drexel University Bipolar electrochemical connection of materials
DE69834257T2 (de) 1997-04-30 2007-01-04 Klingemann, Hans Natürliche killerzelllinien und verfahren zu ihrer verwendung
JP2002513295A (ja) 1997-07-08 2002-05-08 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド １２３種類のヒト分泌タンパク質
US6416973B1 (en) 1997-08-01 2002-07-09 Schering Corporation Nucleic acids encoding mammalian cell membrane protein MDL-1
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
BR9907691B1 (pt) 1998-02-05 2011-05-31 derivado de antìgeno e antìgeno da famìlia mage associado a tumor, seqüência de ácido nucléico, codificando os mesmos, seus usos na preparação de vacina, processo para produção de vacina e vacina.
US6607879B1 (en) 1998-02-09 2003-08-19 Incyte Corporation Compositions for the detection of blood cell and immunological response gene expression
US7001733B1 (en) 1998-05-12 2006-02-21 Rigel Pharmaceuticals, Inc. Methods and compositions for screening for modulations of IgE synthesis, secretion and switch rearrangement
WO2000014257A1 (en) 1998-09-04 2000-03-16 Sloan-Kettering Institute For Cancer Research Fusion receptors specific for prostate-specific membrane antigen and uses thereof
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
ES2706547T3 (es) 1998-12-23 2019-03-29 Pfizer Anticuerpos monoclonales humanos para CTLA-4
US6307024B1 (en) 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
US6790662B1 (en) 1999-03-12 2004-09-14 Ortho-Mcneil Pharmaceutical, Inc. Method of isolating CD8+ cells, and related hybridoma cells antibodies and polypeptides
JP2002541845A (ja) 1999-04-16 2002-12-10 セルテック セラピューティックス リミテッド 合成膜貫通成分
DK1187629T3 (da) 1999-04-19 2005-01-17 Glaxosmithkline Biolog Sa Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
US6747665B1 (en) 1999-05-10 2004-06-08 Ge Medical Systems Global Technology Company, Llc Semi-transparent medical image overlays
US6361714B1 (en) 1999-06-03 2002-03-26 Fuji Photo Film Co., Ltd. Method of preparing barium fluorohalide phosphor
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
US7118751B1 (en) 1999-10-14 2006-10-10 Trubion Pharmaceuticals, Inc. DNA vaccines encoding antigen linked to a domain that binds CD40
EP1284747A2 (en) 2000-05-12 2003-02-26 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
CA2410510A1 (en) 2000-06-02 2001-12-13 Memorial Sloan-Kettering Cancer Center Artificial antigen presenting cells and methods of use thereof
GB0017173D0 (en) 2000-07-12 2000-08-30 Bp Chem Int Ltd Process for the production of olefins
US7732133B2 (en) 2000-07-17 2010-06-08 Chugai Seiyaku Kabushiki Kaisha Screening methods for biologically active ligands
MXPA03002278A (es) 2000-09-14 2004-12-03 Beth Israel Hospital Modulacion de respuestas de la celula t mediadas por il-2 e il-15.
GB0025307D0 (en) 2000-10-16 2000-11-29 Celltech Chiroscience Ltd Biological products
US20020102264A1 (en) 2000-10-18 2002-08-01 Cheung Nai-Kong V. Uses of monoclonal antibody 8H9
US6937446B2 (en) 2000-10-20 2005-08-30 Kabushiki Kaisha Toshiba Magnetoresistance effect element, magnetic head and magnetic recording and/or reproducing system
EP1356066A2 (en) 2000-10-24 2003-10-29 Syngenta Participations AG Control of gene expression in plants
US7446179B2 (en) 2000-11-07 2008-11-04 City Of Hope CD19-specific chimeric T cell receptor
US6706867B1 (en) 2000-12-19 2004-03-16 The United States Of America As Represented By The Department Of Health And Human Services DNA array sequence selection
US20040071671A1 (en) 2001-02-20 2004-04-15 Leturcq Didier J. Cell therapy method for the treatment of tumors
DE60238308D1 (de) 2001-02-20 2010-12-30 Univ Georgia Schnellproduktion monoklonaler antikörper
US7723111B2 (en) 2001-03-09 2010-05-25 The United States Of America As Represented By The Department Of Health And Human Services Activated dual specificity lymphocytes and their methods of use
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US7514537B2 (en) 2001-04-30 2009-04-07 City Of Hope Chimeric immunoreceptor useful in treating human gliomas
US6824974B2 (en) 2001-06-11 2004-11-30 Genorx, Inc. Electronic detection of biological molecules using thin layers
US20030211603A1 (en) 2001-08-14 2003-11-13 Earp David J. Reprogramming cells for enhanced differentiation capacity using pluripotent stem cells
US20030148982A1 (en) 2001-11-13 2003-08-07 Brenner Malcolm K. Bi-spcific chimeric T cells
JP3749873B2 (ja) 2002-03-28 2006-03-01 株式会社東芝 磁気抵抗効果素子、磁気ヘッド及び磁気再生装置
US8535672B2 (en) 2002-04-04 2013-09-17 Yissum Research Development Of The Hebrew University Of Jerusalem Broad-spectrum in-vivo effective superantigen toxin antagonists based on the interaction between CD28 and the superantigen and uses thereof
DE60327199D1 (de) 2002-04-26 2009-05-28 Chugai Pharmaceutical Co Ltd Verfahren zum screening auf agonistische antikörper
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US8263375B2 (en) 2002-12-20 2012-09-11 Acea Biosciences Dynamic monitoring of activation of G-protein coupled receptor (GPCR) and receptor tyrosine kinase (RTK) in living cells using real-time microelectronic cell sensing technology
WO2004028563A1 (en) 2002-09-27 2004-04-08 Genexine Inc. A vaccine enhancing the protective immunity to hepatitis c virus using plasmid dna and recombinant adenovirus
AU2003271904B2 (en) 2002-10-09 2009-03-05 Adaptimmune Limited Single chain recombinant T cell receptors
JP3836788B2 (ja) 2002-12-26 2006-10-25 株式会社東芝 磁気抵抗効果素子、磁気抵抗効果型ヘッドおよび磁気記録再生装置
CA2512110A1 (en) 2002-12-31 2004-07-22 Mmi Genomics, Inc. Compositions, methods, and systems for inferring bovine breed
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
MXPA05014155A (es) 2003-06-27 2006-05-25 Abgenix Inc Anticuerpos dirigidos a los mutantes de delecion de receptor de factor de crecimiento epidermico y sus usos.
US7527944B2 (en) 2003-06-27 2009-05-05 Monell Chemical Senses Center Taste receptors of the T1R family from domestic cat
JP4733635B2 (ja) 2003-07-31 2011-07-27 イミューノメディクス、インコーポレイテッド 抗ｃｄ１９抗体
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
US7682828B2 (en) 2003-11-26 2010-03-23 Whitehead Institute For Biomedical Research Methods for reprogramming somatic cells
US7089052B2 (en) 2004-02-26 2006-08-08 Tanita Corporation Method and system for estimating visceral fat area
EP2439284B1 (en) 2004-03-31 2019-05-08 The General Hospital Corporation Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
AU2005256113B2 (en) 2004-07-09 2011-02-10 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody
FR2873813B1 (fr) 2004-07-30 2006-11-17 Abx Sa Procede et dispositif de caracterisation des composants cellulaires d'un liquide biologique
CA2575490A1 (en) 2004-08-03 2006-02-16 Frank Notka Method for modulating gene expression by altering the cpg content
US7235190B1 (en) 2004-09-02 2007-06-26 Sandia Corporation Nanocluster-based white-light-emitting material employing surface tuning
BRPI0514641A (pt) 2004-09-08 2008-06-17 Wisconsin Alumni Res Found cultivação das células tronco embriÈnica humana
PT1809321E (pt) 2004-10-08 2012-05-17 Us Gov Health & Human Serv Imunoterapia adotiva com sobrevivência aumentada de linfócitos
US7485600B2 (en) 2004-11-17 2009-02-03 Honda Motor Co., Ltd. Catalyst for synthesis of carbon single-walled nanotubes
US7700728B2 (en) 2005-03-24 2010-04-20 Schering Corporation Use of chimeric receptors in a screening assay for identifying agonists and antagonists of cell receptors
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
WO2007001677A2 (en) 2005-05-17 2007-01-04 University Of Connecticut Compositions and methods for immunomodulation in an organism
WO2006133398A2 (en) 2005-06-08 2006-12-14 Invitrogen Corporation In vitro activated donor t-cells to promote transplant engraftment
WO2007002905A1 (en) 2005-06-29 2007-01-04 University Of Miami Antibody-immune cell ligand fusion protein for cancer therapy
JP5299942B2 (ja) 2005-08-09 2013-09-25 オンコセラピー・サイエンス株式会社 ＨＬＡ−Ａ２陽性者用ｇｌｙｐｉｃａｎ−３（ＧＰＣ３）由来癌拒絶抗原ペプチド及びこれを含む医薬
US7341944B2 (en) 2005-09-15 2008-03-11 Honda Motor Co., Ltd Methods for synthesis of metal nanowires
EP1951751B1 (en) 2005-11-14 2017-11-01 Merial, Inc. Gene therapy for renal failure
WO2007067968A2 (en) 2005-12-08 2007-06-14 Novartis Ag Effects of inhibitors of fgfr3 on gene transcription
US8129187B2 (en) 2005-12-13 2012-03-06 Kyoto University Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
EP2206724A1 (en) 2005-12-13 2010-07-14 Kyoto University Nuclear reprogramming factor
ATE533782T1 (de) 2006-01-13 2011-12-15 Univ Pennsylvania Impfstoffe und immuntherapeutika mit codon- optimiertem il-15 und verwendungsverfahren dafür
EP2366787B1 (en) 2006-01-13 2019-12-11 The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services Codon optimized IL-15 and IL-15R-Alpha genes for expression in mammalian cells
CA2643337C (en) 2006-03-01 2016-01-12 Janssen Pharmaceutica N.V. Cancer treatment combining lymphodepleting agent with ctls and cytokines
EP2995950B1 (en) 2006-04-20 2024-01-17 Givaudan SA Method relating to sweetness enhancement
JP5300184B2 (ja) 2006-07-18 2013-09-25 キヤノン株式会社 圧電体、圧電体素子、圧電体素子を用いた液体吐出ヘッド及び液体吐出装置
US7972438B2 (en) 2006-08-30 2011-07-05 Crystal Photonics, Incorporated High-index UV optical materials for immersion lithography
US8323653B2 (en) 2006-09-08 2012-12-04 Medimmune, Llc Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
CN101548008B (zh) 2006-10-04 2013-04-17 詹森药业有限公司 失活的人工抗原提呈细胞的制备及其在细胞疗法中的用途
US20100105136A1 (en) 2006-10-09 2010-04-29 The General Hospital Corporation Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
EP2114990B9 (en) 2007-02-27 2012-03-28 Nuclea Biomarkers LLC Method for predicting the response of NSCLC-patients to treatment by an EGFR-TK inhibitor
US8053615B2 (en) 2007-03-08 2011-11-08 Virent Energy Systems, Inc. Synthesis of liquid fuels and chemicals from oxygenated hydrocarbons
WO2008112886A1 (en) 2007-03-13 2008-09-18 Evident Technologies, Inc. Infrared display with luminescent quantum dots
DK3399025T3 (da) 2007-03-23 2025-06-16 Wisconsin Alumni Res Found Omprogrammering af somatiske celler
US8389282B2 (en) 2007-03-30 2013-03-05 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
WO2008127735A1 (en) 2007-04-13 2008-10-23 Stemline Therapeutics, Inc. Il3ralpha antibody conjugates and uses thereof
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
EP2160404B1 (en) 2007-06-18 2016-08-24 Valorisation-Recherche, Limited Partnership Azapeptides as cd36 binding compounds
EP2173378B1 (en) 2007-06-27 2014-03-19 Admune Therapeutics LLC Complexes of il-15 and il-15ralpha and uses thereof
EP2048237A1 (en) 2007-10-05 2009-04-15 Avir Green Hills Biotechnology Research Development Trade Ag Replication deficient Influenza virus for the expression of heterologous sequences
US20090017050A1 (en) 2007-07-13 2009-01-15 Ventana Medical Systems, Inc. Egfr antigen-binding molecules and uses thereof
US8900816B2 (en) 2007-07-19 2014-12-02 Duke University Assay for anti-EGFRvIII antibodies
CN101903403B (zh) 2007-10-19 2016-03-16 西雅图基因公司 Cd19结合剂及其应用
US9683232B2 (en) 2007-12-10 2017-06-20 Kyoto University Efficient method for nuclear reprogramming
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
PT2242773T (pt) 2008-02-11 2017-09-15 Cure Tech Ltd Anticorpos monoclonais para o tratamento de tumores
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
JP5779090B2 (ja) 2008-04-09 2015-09-16 マックスサイト インコーポレーティッド 新規に単離された細胞の治療組成物の操作および送達
US8591858B2 (en) 2008-05-01 2013-11-26 Honda Motor Co., Ltd. Effect of hydrocarbon and transport gas feedstock on efficiency and quality of grown single-walled nanotubes
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
ES2587395T3 (es) 2008-06-04 2016-10-24 Cellular Dynamics International, Inc. Procedimientos para la producción de células IPS usando un enfoque no vírico
WO2010014784A2 (en) 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
WO2010019569A1 (en) 2008-08-12 2010-02-18 Cellular Dynamics International. Inc. Methods for the production of ips cells
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
CA2735456C (en) 2008-08-26 2021-11-16 City Of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
MY153726A (en) 2008-08-27 2015-03-13 Virent Inc Synthesis of liquid fuels from biomass
MX340972B (es) 2008-10-08 2016-08-02 Intrexon Corp Celulas manipuladas por ingenieria que expresan multiples inmunomoduladores, y uso de las mismas.
WO2010042799A2 (en) 2008-10-09 2010-04-15 Howard Hughes Medical Institute Novel chimeric ligand-gated ion channels and methods of use thereof
EP3450545B1 (en) 2008-10-24 2023-08-23 Wisconsin Alumni Research Foundation Pluripotent stem cells obtained by non-viral reprogramming
CA2753158A1 (en) 2009-02-23 2010-08-26 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to cd19 and their uses
US8877199B2 (en) 2009-05-15 2014-11-04 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services B cell surface reactive antibodies
IT1394774B1 (it) 2009-06-04 2012-07-13 Univ Roma Costrutti esprimenti recettori chimerici, e loro uso per l'attivazione controllata delle risposte di difesa a organismi patogeni in piante
CN105925535A (zh) 2009-06-05 2016-09-07 细胞动力国际有限公司 重编程t细胞和造血细胞的方法
US8900871B2 (en) 2009-08-07 2014-12-02 Kyoto University Method of producing induced pluripotent stem cells using inhibitors of P53
WO2011020047A1 (en) 2009-08-14 2011-02-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of il-15 to increase thymic output and to treat lymphopenia
US8889394B2 (en) 2009-09-07 2014-11-18 Empire Technology Development Llc Multiple domain proteins
JP5934099B2 (ja) 2009-10-01 2016-06-15 アメリカ合衆国 抗血管内皮増殖因子受容体−２キメラ抗原受容体及び癌の治療のためのその使用
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
JP5956342B2 (ja) 2009-11-03 2016-07-27 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ 形質導入Ｔ細胞選択のためのトランケート上皮増殖因子レセプタ（ＥＧＦＲｔ）
KR101775926B1 (ko) 2009-11-04 2017-09-07 셀룰러 다이내믹스 인터내셔널, 인코포레이티드 화학 물질을 이용한 에피솜 재프로그래밍
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
CN102753574B (zh) 2009-12-11 2015-05-20 西马生物医学计划公司 用于免疫治疗和抗肿瘤治疗的缀合物和组合物
US9005967B2 (en) 2010-01-22 2015-04-14 Kyoto University Myc variants improve induced pluripotent stem cell generation efficiency
EP3053932B1 (en) 2010-02-19 2020-07-22 Xencor, Inc. Novel ctla4-ig immunoadhesins
CA2793753C (en) 2010-03-26 2018-06-05 Memorial Sloan-Kettering Cancer Center Antibodies to muc16 and methods of use thereof
WO2011130491A2 (en) 2010-04-14 2011-10-20 Roger Williams Medical Center Methods and compositions for treating hiv
EP2566954B2 (en) 2010-05-04 2022-11-02 Yeda Research and Development Co. Ltd. Immunotherapy using redirected allogeneic cells
AU2011256838B2 (en) 2010-05-17 2014-10-09 Sangamo Therapeutics, Inc. Novel DNA-binding proteins and uses thereof
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
CA2802249A1 (en) 2010-06-15 2011-12-22 Cellular Dynamics International, Inc. Generation of induced pluripotent stem cells from small volumes of peripheral blood
NZ603581A (en) 2010-06-19 2015-05-29 Sloan Kettering Inst Cancer Anti-gd2 antibodies
WO2012012695A2 (en) 2010-07-23 2012-01-26 Fred Hutchinson Cancer Research Center A method for the treatment of obesity
EP2614143B1 (en) 2010-09-08 2018-11-07 Baylor College Of Medicine Immunotherapy of non-small lung cancer using genetically engineered gd2-specific t cells
EP3115373B1 (en) 2010-09-08 2019-08-28 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Chimeric antigen receptors with an optimized hinge region
US9845362B2 (en) 2010-10-08 2017-12-19 The University Of North Carolina At Charlotte Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same
CN102443056B (zh) 2010-10-15 2015-04-29 上海市肿瘤研究所 表皮生长因子受体的外显子缺失变异体
CA2817015A1 (en) 2010-11-09 2012-05-18 Altimab Therapeutics, Inc. Protein complexes for antigen binding and methods of use
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
JP5897035B2 (ja) 2010-12-14 2016-03-30 ユニバーシティ オブ メリーランド，ボルチモア 汎用の抗タグキメラ抗原受容体発現ｔ細胞及びがんを治療する方法
US8642813B2 (en) 2010-12-30 2014-02-04 Virent, Inc. Reductive biomass liquefaction
JP2014509841A (ja) 2011-01-18 2014-04-24 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 癌を治療するための組成物および方法
EA201401134A1 (ru) 2011-02-11 2015-05-29 Мемориал Слоан-Кеттеринг Кэнсер Сентер Hla-рестиктированные пептидоспецифические антигенсвязывающие белки
WO2012129514A1 (en) 2011-03-23 2012-09-27 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
EP3459560B1 (en) 2011-04-08 2021-02-24 The United States of America, as represented by The Secretary, Department of Health and Human Services Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
CN103502439B (zh) 2011-04-13 2016-10-12 因缪尼卡姆股份公司 用于抗原特异性t细胞增殖的方法
US9206257B2 (en) 2011-04-19 2015-12-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies specific for glypican-3 and use thereof
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
US20130001376A1 (en) 2011-06-28 2013-01-03 F2M International Inc. Hose hanger
US9685295B2 (en) 2011-07-28 2017-06-20 The Board Of Trustees Of The University Of Illinois Electron emission device
KR102045349B1 (ko) 2011-08-16 2019-11-15 쇼오트 아게 형광체 조성물 및 그의 제조 방법
US9833476B2 (en) 2011-08-31 2017-12-05 The Trustees Of Dartmouth College NKP30 receptor targeted therapeutics
US9708384B2 (en) 2011-09-22 2017-07-18 The Trustees Of The University Of Pennsylvania Universal immune receptor expressed by T cells for the targeting of diverse and multiple antigens
JP6053688B2 (ja) 2011-10-07 2016-12-27 国立大学法人三重大学 キメラ抗原受容体
JP6267644B2 (ja) 2011-10-20 2018-01-24 アメリカ合衆国 抗ｃｄ２２キメラ抗原受容体
JP6074435B2 (ja) 2011-10-26 2017-02-01 ナショナル キャンサー センター 変異ｃｔｌａ４遺伝子移入ｔ細胞及びこれを含む抗がん免疫治療用組成物
US9272002B2 (en) 2011-10-28 2016-03-01 The Trustees Of The University Of Pennsylvania Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
US9422351B2 (en) 2011-11-03 2016-08-23 The Trustees Of The University Of Pennsylvania Isolated B7-H4 specific compositions and methods of use thereof
WO2013070468A1 (en) 2011-11-08 2013-05-16 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
WO2013071154A1 (en) 2011-11-11 2013-05-16 Fred Hutchinson Cancer Research Center Cyclin a1-targeted t-cell immunotherapy for cancer
US9422360B2 (en) 2011-12-19 2016-08-23 Zhonghao Chenguang Research Institute Of Chemical Industry Company Limited Porcine CD28 receptor, gene for encoding same, and application of same
AU2013216320A1 (en) 2012-02-01 2014-04-03 Compugen Ltd. C10RF32 antibodies, and uses thereof for treatment of cancer
EP2814846B1 (en) 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
CA3285826A1 (en) 2012-02-22 2026-03-02 The Trustees Of The University Of Pennsylvania Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
BR112014020502A2 (pt) 2012-02-22 2019-09-24 Univ Pennsylvania sequência de ácido nucleico isolada, receptor quimérico de antígeno isolado, célula, vetor, e, métodos para estimular uma resposta imune, para fornecer uma imunidade antitumoral, para tratamento de um mamífero, para gerar e para expandir uma população de células - t, e para modular a quantidade de citocina secretada por uma célula -t
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
EP2817330B1 (en) 2012-02-22 2020-07-08 The Trustees of the University of Pennsylvania Use of icos-based cars to enhance antitumor activity and car persistence
CA2868121C (en) 2012-03-23 2021-06-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mesothelin chimeric antigen receptors
AU2013246443B2 (en) 2012-04-11 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting B-cell maturation antigen
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
NZ702108A (en) 2012-05-03 2016-09-30 Hutchinson Fred Cancer Res Enhanced affinity t cell receptors and methods for making the same
CN104395344B (zh) 2012-05-07 2019-08-13 达特茅斯大学理事会 抗b7-h6抗体、融合蛋白及其使用方法
SG10201806573TA (en) * 2012-05-25 2018-09-27 Cellectis Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
CA2875451A1 (en) 2012-06-08 2013-12-12 Kinki University Antibody against transporter and use thereof
KR20210149195A (ko) 2012-07-13 2021-12-08 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 형질도입된 ｔ 세포의 투여 적합성을 평가하는 방법
JP2014022858A (ja) 2012-07-17 2014-02-03 Murata Mfg Co Ltd 電力増幅器
LT2884999T (lt) 2012-08-20 2021-04-12 Fred Hutchinson Cancer Research Center Ląstelinės imunoterapijos būdas ir kompozicijos
WO2014055442A2 (en) 2012-10-01 2014-04-10 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting stromal cells for the treatment of cancer
RU2729401C2 (ru) 2012-10-02 2020-08-06 Мемориал Слоан-Кеттеринг Кэнсер Сентер Композиции и способы для иммунотерапии
WO2014059173A2 (en) 2012-10-10 2014-04-17 Sangamo Biosciences, Inc. T cell modifying compounds and uses thereof
CN104822705B (zh) 2012-10-24 2019-07-12 美国卫生和人力服务部 M971嵌合抗原受体
SG11201505858VA (en) 2013-01-28 2015-09-29 St Jude Childrens Res Hospital A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
SG11201507026WA (en) 2013-02-06 2015-10-29 Anthrogenesis Corp Modified t lymphocytes having improved specificity
JO3529B1 (ar) 2013-02-08 2020-07-05 Amgen Res Munich Gmbh مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
IL305629A (en) 2013-02-15 2023-11-01 Univ California Chimeric antigen receptor and methods of using it
SG11201505896YA (en) 2013-02-20 2015-09-29 Novartis Ag Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
WO2014130635A1 (en) 2013-02-20 2014-08-28 Novartis Ag Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
WO2014138314A1 (en) 2013-03-05 2014-09-12 Baylor College Of Medicine Oncolytic virus
US9434935B2 (en) 2013-03-10 2016-09-06 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof
ES2769574T3 (es) 2013-03-15 2020-06-26 Michael C Milone Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva
AU2014386824B2 (en) * 2013-03-15 2019-05-09 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
US9657105B2 (en) 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
US9393268B2 (en) 2013-03-15 2016-07-19 Thomas Jefferson University Cell-based anti-cancer compositions with reduced toxicity and methods of making and using the same
US9446105B2 (en) 2013-03-15 2016-09-20 The Trustees Of The University Of Pennsylvania Chimeric antigen receptor specific for folate receptor β
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
US9790282B2 (en) 2013-03-25 2017-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
CN104140974B (zh) 2013-05-08 2017-09-29 科济生物医药（上海）有限公司 编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞
EP2997134B1 (en) * 2013-05-14 2020-06-24 Board of Regents, The University of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
CA2913052A1 (en) 2013-05-24 2014-11-27 Board Of Regents, The University Of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
JP6608807B2 (ja) 2013-05-29 2019-11-20 セレクティス Ｒｎａガイドｃａｓヌクレアーゼ系を用いることによって免疫療法のためにｔ細胞を操作するための方法
EP3569253A1 (en) 2013-06-05 2019-11-20 Bellicum Pharmaceuticals, Inc. Methods for inducing partial apoptosis using caspase polypeptides
CA2912389C (en) 2013-06-10 2020-01-28 The General Hospital Corporation D/B/A Massachusetts General Hospital Methods and compositions for reducing immunosupression by tumor cells
US9243068B2 (en) 2013-06-25 2016-01-26 Vaccinex, Inc. Combination of SEMA-4D inhibitors and immunomodulators to inhibit tumors and metastases
EP3027755B1 (en) 2013-08-02 2019-10-09 The Regents of The University of California Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors
CN105682683A (zh) 2013-08-02 2016-06-15 阿杜罗生物科技控股有限公司 结合cd27激动剂以及免疫检查点抑制以用于免疫刺激
SMT202300039T1 (it) 2013-09-13 2023-03-17 Beigene Switzerland Gmbh Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
US11807675B2 (en) 2013-10-03 2023-11-07 The University Of Maryland, Baltimore Nanoparticle based artificial antigen presenting cell mediated activation of NKT cells
EP3054987B1 (en) 2013-10-11 2019-10-09 The United States of America, represented by the Secretary, Department of Health and Human Services Tem8 antibodies and their use
AU2014337367B2 (en) 2013-10-15 2020-04-30 The Scripps Research Institute Peptidic chimeric antigen receptor T cell switches and uses thereof
EP3082802B1 (en) 2013-12-03 2020-02-26 Iomet Pharma Ltd. Tryptophan-2,3-dioxygenase (tdo) and/or indolamine-2,3-dioxygenase (ido) inhibitors and their use
SG10201804750XA (en) 2013-12-06 2018-07-30 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Reduction of inflammatory disease symptoms by short peptides that inhibit signaling through cd28
CA2977839C (en) 2014-02-28 2022-07-26 The Royal Institution For The Advancement Of Learning / Mcgill University Tc-ptp inhibitors as apc activators for immunotherapy
CN122399016A (zh) 2014-03-15 2026-07-17 诺华股份有限公司 使用嵌合抗原受体治疗癌症
TR201910814T4 (tr) 2014-03-19 2019-08-21 Cellectis Kanser immünoterapisi için cd123 spesifik kimerik antijen reseptörleri.
ES2765710T3 (es) 2014-04-03 2020-06-10 Cellectis Receptores de antígeno quimérico específicos de CD33 para la inmunoterapia del cáncer
WO2015188141A2 (en) 2014-06-06 2015-12-10 Memorial Sloan-Kettering Cancer Ceneter Mesothelin-targeted chimeric antigen receptors and uses thereof
US10550197B2 (en) 2014-06-18 2020-02-04 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus CAR-expressing NK-92 cells as cell therapeutic agents
JP6831777B2 (ja) 2014-07-21 2021-02-17 ノバルティス アーゲー Ｃｄ３３キメラ抗原受容体を使用する癌の処置
EP3177640B1 (en) 2014-08-08 2020-05-06 The Board of Trustees of the Leland Stanford Junior University High affinity pd-1 agents and methods of use
EP3712171A1 (en) 2014-08-19 2020-09-23 Novartis AG Treatment of cancer using a cd123 chimeric antigen receptor
DK3186284T3 (da) 2014-08-28 2022-05-09 Bioatla Inc Betinget aktive kimæriske antigenreceptorer til modificerede t-celler
ES2738705T3 (es) 2014-09-19 2020-01-24 Hope City Linfocitos T de receptor de antígeno quimérico coestimulante que se dirigen a IL13R 2
EP3206703B1 (en) 2014-10-14 2021-05-19 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Peptide for treating pancreatic cancer
EP3227317A4 (en) 2014-12-02 2018-04-25 Roger Williams Hospital Methods and compositons for treating cancer
HRP20240357T1 (hr) 2014-12-24 2024-06-07 Autolus Limited Stanica
EP3262166A4 (en) 2015-02-24 2018-08-15 The Regents of The University of California Binding-triggered transcriptional switches and methods of use thereof
CA2977106A1 (en) 2015-02-27 2016-09-01 Icell Gene Therapeutics Llc Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof
BR112017018770A2 (pt) 2015-03-02 2018-04-17 Innovative Cellular Therapeutics CO., LTD. redução da tolerância imunológica induzida por pd-l1
CN114456272A (zh) 2015-04-03 2022-05-10 优瑞科生物技术公司 靶向afp肽/mhc复合体的构建体及其用途
PL3280729T3 (pl) * 2015-04-08 2022-08-22 Novartis Ag Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19
MA41962A (fr) 2015-04-23 2018-02-28 Baylor College Medicine Récepteur antigénique chimérique ciblant le cd5 pour une thérapie adoptive à base de cellules t
GB201507111D0 (en) 2015-04-27 2015-06-10 Ucl Business Plc Nucleic acid construct
EP3098237B1 (en) 2015-05-28 2018-08-01 Universität Zu Köln Anti-toso chimeric antigen receptor and its use
KR102349677B1 (ko) 2015-05-28 2022-01-12 카이트 파마 인코포레이티드 T 세포 요법을 위해 환자를 컨디셔닝하는 방법
WO2016197108A1 (en) 2015-06-05 2016-12-08 Board Of Regents, The University Of Texas System Methods of treatment with natural killer cells matched for killer immunoglobulin receptor type
TWI833684B (zh) * 2015-06-25 2024-03-01 美商生物細胞基因治療有限公司 嵌合抗原受體（ｃａｒ）、組合物及其使用方法
CA2992122A1 (en) 2015-07-16 2017-01-19 Prospect CharterCare RWMC, LLC d/b/a Roger Williams Medical Center Compositions and methods for treating peritoneal cancers
AU2016304060B2 (en) 2015-08-03 2022-09-29 Crage Medical Co., Limited Antibody against glypican-3 and application thereof
AU2016305087B2 (en) * 2015-08-12 2022-01-20 Massachusetts Institute Of Technology Cell surface coupling of nanoparticles
CA2939288A1 (en) 2015-08-28 2017-02-28 Rolls-Royce High Temperature Composites, Inc. Ceramic matrix composite including silicon carbide fibers in a ceramic matrix comprising a max phase compound
EP3349791A1 (en) 2015-09-15 2018-07-25 Board of Regents, The University of Texas System T-cell receptor (tcr)-binding antibodies and uses thereof
ES2803728T3 (es) 2015-10-05 2021-01-29 Prec Biosciences Inc Células genéticamente modificadas que comprenden un gen de región constante alfa del receptor de linfocitos T humano modificado
WO2017075537A1 (en) 2015-10-30 2017-05-04 Aleta Biotherapeutics Inc. Compositions and methods for treatment of cancer
TWI724056B (zh) 2015-11-19 2021-04-11 美商卡默森屈有限公司 Ｃｘｃｒ２抑制劑
TWI734715B (zh) 2015-11-19 2021-08-01 美商卡默森屈有限公司 趨化因子受體調節劑
MX2018006789A (es) 2015-12-03 2019-02-13 Juno Therapeutics Inc Receptores quimericos modificados y composiciones y metodos relacionados.
WO2017093969A1 (en) * 2015-12-04 2017-06-08 Novartis Ag Compositions and methods for immunooncology
AU2016374497B2 (en) 2015-12-16 2022-03-10 The Walter And Eliza Hall Institute Of Medical Research Inhibition of cytokine-induced SH2 protein in NK cells
JP7012645B2 (ja) 2016-01-11 2022-01-28 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー キメラタンパク質および免疫治療の方法
WO2017123559A2 (en) 2016-01-11 2017-07-20 The Board Of Trustees Of The Leland Stanford Junior University Chimeric proteins and methods of regulating gene expression
CN113082201B (zh) 2016-04-01 2024-07-05 上海斯丹赛生物技术有限公司 刺激t细胞介导的对表达抗原的细胞群的免疫应答的方法
IL263874B2 (en) 2016-06-22 2025-02-01 David Klatzmann Genetically modified T lymphocytes
CN109562126A (zh) * 2016-06-24 2019-04-02 美商生物细胞基因治疗有限公司 嵌合抗原受体(car)、组合物及其使用方法
EP3493827A4 (en) 2016-08-04 2020-02-26 Memorial Sloan-Kettering Cancer Center COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY
EP3532075A4 (en) 2016-10-27 2020-07-08 Intima Bioscience, Inc. VIRAL METHODS OF MANUFACTURING GENETICALLY MODIFIED CELLS
SG11202010763VA (en) * 2018-05-03 2020-11-27 Univ Texas Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blockade

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007528862A (ja) * 2003-07-16 2007-10-18 アールブイエックス セラピューティクス， インコーポレイテッド ＴＧＦ−βの効果を下方制御するための化合物および方法
JP2010508850A (ja) * 2006-11-13 2010-03-25 サンガモ バイオサイエンシズ インコーポレイテッド ヒトグルココルチコイド受容体遺伝子座の修飾のための方法および組成物
WO2012136231A1 (en) * 2010-09-08 2012-10-11 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Interleukin 15 as selectable marker for gene transfer in lymphocytes
US20140255363A1 (en) * 2011-09-16 2014-09-11 Baylor College Of Medicine Targeting the tumor microenvironment using manipulated nkt cells
WO2017023803A1 (en) * 2015-07-31 2017-02-09 Regents Of The University Of Minnesota Modified cells and methods of therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
C.SAHM, ET AL., CANCER IMMUNOLOGY IMMUNOTHERAPY, vol. 61, JPN6022020682, 2012, pages 1451 - 1461, ISSN: 0004969252 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023504782A (ja) * 2019-11-27 2023-02-07 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｂ細胞のｃａｒ形質導入とｃｒｉｓｐｒ遺伝子編集との大規模での組み合わせ
JP7698321B2 (ja) 2019-11-27 2025-06-25 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｂ細胞のｃａｒ形質導入とｃｒｉｓｐｒ遺伝子編集との大規模での組み合わせ
JP2023540022A (ja) * 2020-08-24 2023-09-21 シャリテ－ウニベルジテーツメディツィン ベルリン チェックポイント阻害分子及び免疫刺激性サイトカインをコードするキメラ抗原受容体構築物、並びにＣＤ４４ｖ６を認識するＣＡＲ発現細胞
JP2024532876A (ja) * 2021-08-24 2024-09-10 アストラゼネカ・アクチエボラーグ プライマリー免疫細胞を作製するための方法

Also Published As

Publication number Publication date
US20200085872A1 (en) 2020-03-19
WO2018195339A1 (en) 2018-10-25
EP3612210A1 (en) 2020-02-26
US20220265718A1 (en) 2022-08-25
US11344578B2 (en) 2022-05-31
CA3060443A1 (en) 2018-10-25
KR20240059648A (ko) 2024-05-07
JP2023109901A (ja) 2023-08-08
EP3612210A4 (en) 2021-01-27
AU2018256436B2 (en) 2024-12-05
AU2018256436A1 (en) 2019-11-07
EP4779017A2 (en) 2026-07-22
KR20190142775A (ko) 2019-12-27
US20260102335A1 (en) 2026-04-16
CN110753555A (zh) 2020-02-04

Similar Documents

Publication Publication Date Title
US20220265718A1 (en) Immune cells expressing engineered antigen receptors
JP7672702B2 (ja) 機能および抑制性環境に対する抵抗性を増強するための免疫細胞のマルチプレックスゲノム編集
JP2024045179A (ja) 免疫チェックポイント遮断によりキメラ抗原受容体を発現するように操作されたナチュラルキラー細胞
US20230051406A1 (en) Genetically modified natural killer cells and methods of use thereof
CN114615886A (zh) 细胞冷冻保存培养基
US20250114452A1 (en) Lat activating chimeric antigen receptor t cells and methods of use thereof
US20240390419A1 (en) Cd3 epsilon chimeric antigen receptors and methods of use thereof
CA3163209A1 (en) Large-scale combined car transduction and crispr gene editing of t cells
EA048895B1 (ru) Мультиплексное редактирование генома иммунных клеток для повышения функциональности и устойчивости к подавляющей среде

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200115

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210406

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210406

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220525

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221122

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230123